logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 20 of 36 Items
Showing 1 - 20 of 36 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Review

Cutaneous leishmaniasis in Afghanistan

Rahimi BA, Ghatee MA, Habib MN, Farooqi K, Ritmeijer K,  et al.
2025-05-07 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2025-05-07 • Transactions of the Royal Society of Tropical Medicine and Hygiene

Old World cutaneous leishmaniasis (OWCL) is a sand fly-transmitted skin infection caused by Leishmania species that extends from West Africa to China. Afghanistan probably has the hig...

Journal Article
|
Commentary

Leishmaniasis in Syria – A call for action of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) study groups for infections in travellers and migrants (ESGITM) and for clinical parasitology (ESGCP)

Abbara A, González-Sanz M, AlKharrat A, Khalife M, Elferruh Y,  et al.
2025-04-02 • Travel Medicine and Infectious Disease
2025-04-02 • Travel Medicine and Infectious Disease
Journal Article
|
Review

Kala-azar elimination in India: Reflections on success and sustainability

Pandey DK, Alvar J, den Boer M, Jain S, Gill N,  et al.
2025-03-03 • International Health
2025-03-03 • International Health

The incidence and mortality of kala-azar (KA, visceral leishmaniasis) in India have fallen drastically in the past few years, and in 2023 the reported KA incidence reached the thresho...

Journal Article
|
Research

Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India

Sundar S, Alves F, Ritmeijer K, den Boer M, Forsyth C,  et al.
2025-02-25 • PLOS Neglected Tropical Diseases
2025-02-25 • PLOS Neglected Tropical Diseases

BACKGROUND

Visceral leishmaniasis (VL) is a vector-borne disease caused by Leishmania parasites and transmitted by sand fly bites, targeted for elimination in I...

Journal Article
|
Commentary

Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in eastern Africa

Chu WY, Verrest L, Younis BM, Musa AM, Mbui J,  et al.
2024-12-16 • Journal of Infectious Diseases
2024-12-16 • Journal of Infectious Diseases

Treatment regimens for post-kala-azar dermal leishmaniasis (PKDL) are usually extrapolated from those for visceral leishmaniasis (VL), but drug pharmacokinetics (PK) can differ due to...

Journal Article
|
Research

Chronic high-level parasitemia in HIV-infected individuals with or without visceral leishmaniasis in an endemic area in Northwest Ethiopia: Potential superspreaders?

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H,  et al.
2024-07-19 • Clinical Infectious Diseases
2024-07-19 • Clinical Infectious Diseases

Background

People with human immunodeficiency virus (PWH) with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas wi...

Conference Material
|
Video

Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review

Wilson JM
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|
Slide Presentation

Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review

Wilson JM, Chowdhury F, Hassan S, Harriss E, Alves F,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|
Abstract

Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review

Wilson JM, Chowdhury F, Hassan S, Harriss E, Alves F,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Visceral leishmaniasis (VL) is a neglected tropical disease prevalent in populations affected by poverty, war, and famine. Without effective treatment, death is the norm...
Journal Article
|
Research

Persistent T cell unresponsiveness associated with chronic visceral leishmaniasis in HIV-coinfected patients

de Vrij N, Pollmann J, Rezende AM, Ibarra-Meneses AV, Pham TT,  et al.
2024-05-03 • Communications Biology
2024-05-03 • Communications Biology
A large proportion of HIV-coinfected visceral leishmaniasis (VL-HIV) patients exhibit chronic disease with frequent VL recurrence. However, knowledge on immunological determinants underl...
Journal Article
|
Review

Blood transfusion in the care of patients with visceral leishmaniasis: a review of practices in therapeutic efficacy studies

Dahal P, Singh-Phulgenda S, Wilson JM, Cota G, Ritmeijer K,  et al.
2024-05-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2024-05-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
Blood transfusion remains an important aspect of patient management in visceral leishmaniasis (VL). However, transfusion triggers considered are poorly understood. This review summarises...
Journal Article
|
Editorial

Therapeutic strategies against leishmania and trypanosoma

Santos ALS, Rodrigues IA, d’Avila-Levy CM, Sodré CL, Ritmeijer KKD,  et al.
2023-10-19 • Pathogens
2023-10-19 • Pathogens
Human African trypanosomiasis (also known as sleeping sickness, with Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense as etiological agents), American trypanosomiasis (als...
Conference Material
|
Slide Presentation

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Abstract

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The parasitic disease visceral leishmaniasis (VL) is most commonly caused by Leishmania donovani in eastern Africa, currently the region with highest burden worldwide. C...
Journal Article
|
Research

Prevalence and determinants of asymptomatic Leishmania infection in HIV-infected individuals living within visceral leishmaniasis endemic areas of Bihar, India

Mahajan R, Owen SI, Pandey K, Kazmi S, Kumar V,  et al.
2022-08-30 • PLOS Neglected Tropical Diseases
2022-08-30 • PLOS Neglected Tropical Diseases
People living with HIV (PLHIV) have an increased risk of developing visceral leishmaniasis (VL) and poor outcomes compared to HIV negative individuals. Here, we aim to establish the prev...
Journal Article
|
Research

The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994

Seaman J, Mercer A, Sondorp H
1996-08-01 • International Journal of Epidemiology
1996-08-01 • International Journal of Epidemiology
BACKGROUND: Although endemic in parts of southern Sudan, visceral leishmaniasis (VL) had not been reported in Western Upper Nile (WUN) until an epidemic was confirmed in 1989. A combinat...
Journal Article
|
Research

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA,  et al.
2005-12-01 • Lancet Infectious Diseases
2005-12-01 • Lancet Infectious Diseases
The state of Bihar in India carries the largest share of the world's burden of antimony-resistant visceral leishmaniasis. We analysed clinical studies done in Bihar with different treatm...
Protocol
|
Research Protocol

Secondary prophylaxis of visceral leishmaniasis relapses in HIV co-infected patients using pentamidine as a prophylactic agent: a prospective cohort study

Diro EGJ, Griensven JV, Woldegebreal T, Belew Z, Taye M,  et al.
2018-07-01
2018-07-01
2.1 OBJECTIVES
2.1.1 General objective:

To document the effectiveness, safety and feasibility of monthly PM secondary prophylaxis (PSP) in VL/HIV co-infected patients t...
Journal Article
|
Research

A neglected disease of humans: a new focus of visceral leishmaniasis in Bakool, Somalia

Marlet MVL, Wuillaume F, Jacquet D, Quispe KW, Dujardin JC,  et al.
2008-02-07 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2008-02-07 • Transactions of the Royal Society of Tropical Medicine and Hygiene
Visceral leishmaniasis (VL) was observed in children in Bakool region, Somalia, an area where VL has not been reported before. We describe the extent of the problem in this war- and fami...
Journal Article
|
Review

Leishmaniasis

Burza S, Croft SL, Boelaert M
2018-09-01 • Lancet
2018-09-01 • Lancet
Leishmaniasis is a poverty-related disease with two main clinical forms: visceral leishmaniasis and cutaneous leishmaniasis. An estimated 0·7-1 million new cases of leishmaniasis per yea...